Pharmacologic eigenvalues: beating the rap on bone marrow failure
- PMID: 20972329
- PMCID: PMC2965004
- DOI: 10.1172/JCI45060
Pharmacologic eigenvalues: beating the rap on bone marrow failure
Abstract
Patients suffering from sustained acute or chronic illness often have decreased white blood cell and platelet counts as well as anemia, and bone marrow studies routinely show only decreased numbers of blood precursor cells. While much has been recently learned about the cause of isolated anemia, the pathogenesis of true bone marrow failure (i.e., low bone marrow cellularity and low counts in multiple blood lineages) has remained elusive. In this issue of the JCI, Chen et al. present evidence that overactivation of mammalian target of rapamycin signaling in HSCs is found in two mouse models of bone marrow failure, and they show that treatment with rapamycin significantly normalizes the low blood counts.
Comment on
-
Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice.J Clin Invest. 2010 Nov;120(11):4091-101. doi: 10.1172/JCI43873. Epub 2010 Oct 25. J Clin Invest. 2010. PMID: 20972332 Free PMC article.
References
-
- Hexner EO, et al. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biol Blood Marrow Transplant. 2007;13(10):1135–1144. doi: 10.1016/j.bbmt.2007.06.010. - DOI - PubMed
-
- Essers MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904–908. - PubMed
